Related Experiment Videos

Effect of modified wuzi yanzong granule on patients with mild cognitive impairment from oxidative damage aspect

Xue-mei Wang1, Hong Fu, Geng-xin Liu

  • 1Department of Integrated Chinese and Western Medicine of Peking University First Hospital, Beijing, 100034, China. wangxuemei64@sohu.com

Chinese Journal of Integrative Medicine
|January 9, 2008
PubMed
Abstract

Insights

Modified Wuzi Yanzong Granule (WYG) improved memory function in mild cognitive impairment (MCI) patients. WYG treatment reduced oxidative stress markers and mitochondrial DNA damage, suggesting it may delay MCI progression.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Mild cognitive impairment (MCI) is characterized by memory decline and increased oxidative stress.
  • Biomarkers such as serum superoxide dismutase (SOD), malondialdehyde (MDA), leukocyte mitochondrial DNA (mtDNA) deletion rate, and beta-amyloid protein (A beta(1-28)) are associated with MCI.
  • Identifying effective interventions to slow MCI progression is crucial.

Purpose of the Study:

  • To evaluate the efficacy of modified Wuzi Yanzanzong Granule (WYG) in improving memory function in MCI patients.
  • To assess the impact of WYG on oxidative stress markers and mtDNA integrity in MCI.
  • To explore the therapeutic potential of WYG in mitigating MCI progression.

Main Methods:

  • A randomized controlled trial involving 36 MCI patients and 20 healthy controls.
  • Participants were assigned to receive either WYG or a placebo for 3 months.
  • Measurements included memory function, serum SOD and MDA levels, leukocyte mtDNA deletion rate, and A beta(1-28) levels before and after treatment.

Main Results:

  • MCI patients exhibited significantly lower memory quotient and SOD activity, and higher MDA levels, A beta(1-28) levels, and mtDNA deletion rates compared to controls.
  • WYG treatment significantly improved memory quotient and SOD activity, while reducing MDA levels, A beta(1-28) levels, and mtDNA deletion rates in MCI patients.
  • The treated group showed significantly lower mtDNA deletion rates and A beta(1-28) content compared to the placebo group.

Conclusions:

  • Modified WYG demonstrates potential in enhancing memory function in individuals with MCI.
  • The therapeutic effects of WYG may be attributed to its antioxidant properties, improved free radical metabolism, and reduced oxidative damage to leukocyte mtDNA.
  • WYG shows clinical promise for delaying the progression of mild cognitive impairment.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...